Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

The user "OP" is frustrated with hair loss despite using oral minoxidil, topical finasteride, and oral dutasteride. Other users suggest keto shampoo, lifestyle changes, and low light laser therapy.

Betacarotene's effect on hair loss is discussed, with concerns about excessive vitamin A. The user also questions if 15mg melatonin impacts vitamin A levels.

The conversation discusses the effectiveness of Exosomes as a hair loss treatment. A user recalls a doctor on Youtube showcasing successful results from using Exosomes.

User considers making Zix topical solution with ethanol/alcohol for hair loss treatment. Asks if crushing b6 and zinc into stemoxydine is possible.

Finasteride is not effectively stopping hair loss for the user, who is considering alternatives like Dutasteride, Minoxidil, and microneedling, but is hesitant about surgery or hair systems. The user expresses frustration with the lack of effective treatments for male pattern baldness.

Hair loss may be linked to DHT, which can both suppress and increase inflammation, potentially as a defense mechanism. Treatments like Minoxidil, Finasteride, and RU58841 are discussed, but the exact cause of hair loss remains unclear.

Exosome therapy for hair loss is questioned for its effectiveness and authenticity. Users express skepticism, citing manipulated photos and high costs.

Kopexil (Aminexil) is not approved as a drug in the US and Europe because it is marketed as a cosmetic, which requires less testing and regulation. L'Oreal's 1.5% Aminexil is noted to reduce hair shedding, but its efficacy as a drug is not proven.

PRP treatments have been effective for the user, with a new recommendation of using a high-quality plasma kit once a year. The user seeks experiences with this specific PRP approach.

GHK-Cu is a potent inhibitor of the type 1 5-alpha reductase enzyme in hair follicles, which may reduce hair loss without the side effects associated with type 2 5-alpha reductase inhibitors. The user previously experienced side effects with 5-alpha reductase inhibitors and is considering GHK-Cu as an alternative.

Verteporfin is discussed as a potential treatment for scarring alopecia. Minoxidil is suggested as an alternative treatment.

The conversation discusses hair loss treatments, with the original poster considering joining a clinical trial for setipiprant after experiencing side effects from finasteride and disinterest in minoxidil. Some users express skepticism about setipiprant's effectiveness, while others encourage participation in the trial for potential benefits.

Kintor Pharma successfully dosed the first patient in a Phase II trial for KX-826 for acne vulgaris. Users are more interested in results for male pattern baldness (MPB).

Dr. Bloxham's new channel will discuss verteporfin and other future hair loss treatments. Users express interest and hope for the effectiveness of these treatments.

A 22-year-old male experiencing hair loss suspects androgenetic alopecia (AGA) and possibly telogen effluvium (TE), with a noted improvement in scalp itch after adopting a gluten-free diet. He is advised to consider treatments like finasteride or minoxidil and to check iron and ferritin levels.

PP405 shows some hair growth after 4 weeks, but results are debated and expectations should be tempered. Some users compare it to minoxidil or finasteride, questioning its effectiveness and commercialization timeline.

Prolonged use of topical minoxidil and finasteride can lead to neuroendocrine and autonomic dysfunction, causing severe sensitivity and side effects. Recovery involves avoiding these treatments, supporting neurosteroid recovery, calming the sympathetic system, and rebuilding scalp health naturally.

The conversation is about hair loss treatments, specifically the anticipation for the release of a new treatment, GT20029, by 2028. Users are discussing their experiences with current treatments like finasteride and dutasteride, and the potential of future treatments, including FAK inhibitors and verteporfin trials.

PP405 shows potential for hair growth, with 31% of advanced balding men experiencing over 20% increase in hair density in 8 weeks. However, skepticism persists due to selective data presentation and lack of long-term results, with comparisons to treatments like minoxidil and finasteride.

Stem-cell hair transplants could potentially create thousands of grafts from a single donor graft, offering a solution for hair loss with DHT-resistant hair. Companies like Stemson Therapeutics and OrganTech are working on this technology, which may become available in the future, possibly reducing the cost and making it widely accessible.

Pyrilutamide's mainstream product release date is discussed. Side effects found in studies are also questioned.

Potential treatments for hair loss, specifically the combination of liquid minoxidil and pyrilutamide, with some suggesting that adding finasteride may be beneficial.

The conversation discusses a user's plan to inject NAD+ and GHK-Cu into their scalp to improve hair health, with concerns raised about the risks of infection and necrosis. Alternatives like finasteride, dutasteride, microneedling, oral minoxidil, and scalp massages are suggested.

The conversation is about someone looking for specific side effects reported in clinical trials for GT20029, a hair loss treatment. No results or data were found on the clinical trials site.

Cyproterone Acetate stopped hair loss and led to regrowth on the temples for a transgender individual, which is considered a good sign. Unlike Minoxidil and Finasteride, which can cause initial shedding, Cyproterone did not cause shedding.

The conversation discusses anticipation for CB-03-01, a potential new hair loss treatment that may be more effective and have a cleaner safety profile than finasteride. Users are hopeful but cautious, discussing current treatments like minoxidil, nizoral, and dermarolling, and the possibility of combining them with CB-03-01 for better results.

Pelage, backed by Google Ventures, is seen as a promising company potentially finding a cure for hair loss using stem cell activation. There is skepticism and optimism among users, with some awaiting results from ongoing trials.

The user is unsatisfied with their hair transplant and is considering another transplant, PRP, exosomes, or stem cells. They currently use topical minoxidil, dutasteride, and tretinoin.

The user is experiencing significant hair loss and has tried treatments like PRP therapy, topical and oral Minoxidil, Finasteride, and dietary changes, with limited success. They are concerned about losing more hair before a scheduled hair transplant and are advised to postpone the transplant to allow medications more time to work.

The conversation discusses using verteporfin for hair regrowth and minimizing scarring after hair transplants. Some individuals plan to self-administer verteporfin, potentially in combination with microneedling, as an alternative to hair transplants.